Commentary raises bone, reproductive and eating disorder questions about adolescent GLP-1 use

A commentary published in the Journal of Pediatric and Adolescent Gynecology in June 2026 is raising questions about how much doctors and families actually know about the long-term effects of GLP-1 receptor agonists in teenagers ^[1][2]. The drugs, which include semaglutide (Ozempic, Wegovy, Rybelsus) and liraglutide, are increasingly prescribed to adolescents for obesity and type 2 diabetes, and there is growing interest in using them for polycystic ovary syndrome, which the authors refer to by a newer term, polyendocrine metabolic ovarian syndrome ^[2].

The commentary's central concern is timing. Adolescence is described as the critical window when the body builds most of its lifetime peak bone mass, and the authors say rapid, drug-induced weight loss during this period could theoretically interfere with that process ^[1][2]. Clinical trials of liraglutide and semaglutide in adolescents with obesity did show significant weight reduction without short-term harm to growth or puberty ^[2]. But the authors stress that no long-term skeletal data exist for this age group, so whether bone mineral accrual is affected years later is simply not known ^[1][2].

The commentary draws on adult research to fill in some of the gaps, noting that adult studies have linked GLP-1-driven weight loss to modest reductions in bone mineral density, while structured exercise appeared to lessen that effect ^[2]. Adult studies also showed improvements in insulin resistance and menstrual regularity with these drugs ^[2]. But the authors caution that adult findings do not automatically apply to teenagers, whose bones and reproductive systems are still developing.

On reproductive health, the commentary points out that GLP-1 drugs are not recommended during pregnancy, and there is no data at all on reproductive outcomes in people who took these medications as adolescents ^[1][2]. That is a notable gap given the rising interest in prescribing these drugs to teenage girls with PCOS-related conditions, a population that will eventually face questions about fertility and pregnancy.

The authors also flag a psychosocial concern: the strong appetite-suppressing effect of these drugs could be misused or could worsen eating disorders in a population already vulnerable to body image pressure ^[1][2]. This is described as a concern rather than a documented outcome backed by adolescent-specific data in the commentary.

Why it matters for patients

For families weighing GLP-1 treatment for a teenager, this commentary does not report new trial results or a safety alert. It is a call for caution built on the fact that certain long-term questions—bone density years later, effects on future fertility, and eating disorder risk—have not been studied directly in adolescents ^[1][2]. The authors suggest that bone health monitoring, resistance exercise, contraceptive counseling, and screening for disordered eating may become important considerations when these therapies are used in this age group ^[2]. That is a suggestion for clinical practice, not a guarantee that current prescribing is unsafe.

Parents and patients may want to understand that the short-term data on weight loss and lack of interference with growth and puberty come from actual pediatric trials, while the bone density concerns are drawn largely from adult studies extended by analogy to teenagers ^[2]. The distinction matters because it shows where real evidence ends and where informed speculation begins.

What happens next

The commentary does not specify new trials or regulatory action. It calls for careful patient selection and monitoring when GLP-1 drugs are considered for adolescents, but no dated milestones for additional pediatric bone or reproductive studies are mentioned in the source material ^[1][2]. Whether professional societies or regulators respond with updated guidance is not yet known from what has been published.